




Company Introduction

– Yung Shin Taiwan –



Yung Shin Group is a global healthcare venture with 10 international affiliates operating across different regions



Here we are

YUNG SHIN PHARM. IND. CO. LTD.



CARLSBAD TECH. INC.



Y.S.P. INDUSTRIES (M) SDN. BHD.



CHEMIX INC.



YUNG ZIP CHEMICAL IND. CO. LTD.



Vetnostrum Animal Health Co., Ltd.





Company Profile

Incorporation : August 1965

TSE Listing : May 1993

Chairman : Mr. Chi-Li Lee

Total Employees : 1,223 (as of Dec. 2025)

Revenue : USD 170 Million (2025)

Location : Taichung, Taiwan

Business Outline : R&D, Manufacturing and Commercialization

- Pharmaceuticals
(API and Finished product)
- Medical Device
- Health Supplements
- Cosmeceutical Products
- Fine Chemicals



Mission

Providing the best products to improve human health

Vision

Guarding health, creating beauty, and delivering happiness




Company History

Predecessor

Pioneering Stage


Growth Stage

Transition Stage





Organization(Yung Shin Taiwan)





Integrated R&D and Manufacturing Expertise




Fermentation

- **Broad Microbial Platforms:** Bacillus, Yeast and Fungi
- **Strain Improvement**
- **Structurally complex API produced via biotransformation**
- **Scalable Fermentation Capacity:** from 50L to 50,000L Fermenters



Chemical Synthetic

- **Extensive Organic Chemistry expertise :** hydrogenation, bromination, solid-phase peptide synthesis, name reaction, column purification, micronization... etc.
- **Process Optimization**
- **Flexible Production Scale:** from lab scale to commercialization (up to hundreds of kgs)
- **Peptides drugs**



Topical Dosage Forms

Cream, Gel, Ointment, Suppository



Solid Dosage Forms

Modified-Release Capsule/Tablet (Delayed-Release, Multiple-Unit Pellets, Repeated-Release, Solid Dispersion), Matrix Tablet, Multiple-Layer Tablet, Orally-Disintegrating Tablet, Powder for Suspension, Syrup



Injectable Dosage Forms

Liposomal, Lyophilized, Powder, Solution, Suspension



Comprehensive Formulation Platforms

Microspheres, Liposomes



Intelligent Quality Management System

SAP, APS, EQMS, LIMS, Empower



Up to OEB5 Production Lines and High Potent/Cytotoxic Facilities

Oncology, Penicillin and Cephalosporin





Capacity

Remark: “M”=“Million” ; “B”=“Billion”




Solid/Semi-Solid Site	Oncology Site	Injection Site	Cephalosporin Site	Penicillin Site	API Site
Oral: • Capsule: 800M • Tablet: 2.5B • Syrup: 3.2M bottles Topical: • Cream/Gel/Oint.: 108,000kg • Suppository: 24M units	Injectable: • Lyophilization: 267,250 vials • Solution: 415,000 vials	Injectable: • Lyophilization: 680,000 Vials (20R) • Powder: 3.6M Vials • Solution: 28.1M Ampoules 19.5M Vials	Oral: • Capsule: 112M • Tablet: 50M • Powder for suspension: 1.05M bottles Injectable: • Powder: 3.75M Vials	Oral: • Capsule: 140M • Tablet: 50M Injectable: • Powder: 3.75M Vials	Chemical synthesis • General: 20L~6T Reactor • Oncology: 20L~50L Reactor • High potent: 20L~100L Reactor Fermentation • 500L~50T Fermentor





Global GMP Milestone

Manufacturing operations covered by US FDA Inspection: TCM, TTR, TCT, CHG, POW, CSN, SVT and SVL






Future Plan



*Expandable area for future dedicated production in New Oral Solid Dosage Form Site.

New Injectable Site-Lyophilization:


- Target Operation Year: 2029
- Capacity: 1.6~2 Million vials
- Manufacturing Process:



New Oral Solid Dosage form Site :

- Target Operation Year: 2030
- Capacity: : 2.8 Billion Tablets, 1.1 Billion Capsules


➤ Manufacturing Process:





Global Presence

We proudly serve partners in 30+ countries.



- ◆ **North America:** United States, Canada, Mexico
- ◆ **Asia:** Japan, China, Afghanistan, Bangladesh, Brunei, Cambodia, Hong Kong, India, Indonesia, Malaysia, Mongolia, Myanmar, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam, Laos
- ◆ **Latin America:** Argentina, Argentina, Brazil, Colombia, Costa Rica, El Salvador, Guatemala, Panama, Peru
- ◆ **Africa:** Ghana, Egypt, Madagascar, Morocco
- ◆ **Oceania:** Australia
- ◆ Kurdistan



Partnering for Success

Our Partnering Offerings

- Licensing (Product/Technology)
- Co-Development
- Contract Services (CDMO/CMO)

Our Commitments to Partners

- Long-term partnerships
- Maximum flexibility at the highest quality level
- Full support on all collaborative projects



Thank you



Sales Regions & Contact Information

USA / Canada / Australia / ASEAN Countries / Hong Kong	Europe / Enzymes / Latin America	API / Middle East / Mongolia / Africa	China / Taiwan / Japan
Amanda Chen u51097@yungshingroup.com Hailey Hsu u52629@yungshingroup.com	Danny Lee Danny.lee@yungshingroup.com Kate Chang u52348@yungshingroup.com	Cupid Lee u50310@yungshingroup.com Artie Su u52621@yungshingroup.com	Anne Peng anne.peng@yungshingroup.com Stella Hsiao u49727@yungshingroup.com